Annexin A5 in Patients With Severe COVID-19 Disease: A Single Centre, Randomized, Double-blind, Placebo-controlled Pilot Trial
Latest Information Update: 10 Mar 2023
At a glance
- Drugs SY 005 (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease; Sepsis
- Focus Therapeutic Use
- Acronyms AX-COVID
Most Recent Events
- 07 Mar 2023 Status changed from recruiting to completed.
- 23 Apr 2021 Status changed from not yet recruiting to recruiting.
- 15 Feb 2021 New trial record